1448992-66-2

Upstream product

• 1448992-65-1 {3-[2-(acetylamino-methyl)-phenoxy]-propyl}-carbamic acid tert-butyl ester 
• 58885-58-8 N-tert-butoxycarbonyl-3-aminopropanol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 80311-94-0 N-(2-hydroxybenzyl)acetamide 
• 63452-53-9 N-acetyl-2-methoxybenzylamine 
• 6850-57-3 2-methoxybenzylamine 

Downstream Products

• 1448992-67-3 [ (2-{3-[2-(3-tert-butoxycarbonylamino-propoxy)-benzyl]-ureido}thiazole-4-carbonyl)-amino]-acetic acid methyl ester 
• 1448992-69-5 [(2-{3-[2-(3-tert-butoxycarbonylamino-propoxy)-benzyl ]-ureido}-thiazole-4-carbonyl)-amino ]-acetic acid 
• 1448992-70-8 methyl-3-(2-(2-(3-(2-(3-(tert-butoxycarbonylamino)propoxy) benzyl)ureido )thiazole-4-carboxamido )acetamido )-3-phenylpropanoate 
• 1448992-73-1 (R)-ethyl-3-(2-(2-(3-(2-(3-(tert-butoxycarbonylamino)propoxy)benzyl)ureido)thiazole-4-carboxamido)acetamido)-3-(pyridin-3-yl)propanoate 

Relevant academic research and scientific papers

INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3

The invention relates to compounds of formula (I): wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula (I) for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to alpha-V-beta-3 integrin antagonists to target cells expressing alpha-V-beta-3.